Clinical Trial Update: Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

This document summarizes a Phase 2 trial evaluating the combination of gemcitabine and epirubicin for malignant mesothelioma, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Epirubicin (epirubicin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Malignant Mesothelioma | Phase 2 | Status: COMPLETED